The 79th World Health Assembly (WHA), held in Geneva from May 18 to 26, 2026, adopted a landmark resolution on hemophilia and other inherited bleeding disorders. The resolution, co-sponsored by multiple member states, aims to strengthen national health systems to provide better diagnosis, treatment, and care for patients with these conditions.
According to the World Health Organization (WHO), hemophilia affects approximately 1 in 10,000 people globally, but many cases remain undiagnosed, especially in low- and middle-income countries. The resolution calls for improved access to clotting factor concentrates, comprehensive care centers, and national registries to track patient outcomes.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, welcomed the resolution, stating that it 'represents a critical step toward ensuring that no one is left behind in accessing life-saving treatment for bleeding disorders.' The resolution also emphasizes the need for affordable medicines and technologies, including gene therapies that have shown promise in clinical trials.
The adoption of this resolution builds on previous WHO efforts, including the 2014 World Health Assembly resolution on hemophilia, and aligns with the WHO's Thirteenth General Programme of Work (2019ā2025) to achieve universal health coverage.
